News
AZN
67.75
-0.75%
-0.51
What Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors
TipRanks · 18h ago
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approved AstraZeneca and Sanofi’s Beyfortus for the prophylaxis of lower respiratory tract disease (RSV) in infants. The approval is in line with existing Japanese guidelines. Astra Zeneca has also taken legal action against a federal drug discount program in Arkansas.
Benzinga · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), AstraZeneca (AZN)
TipRanks · 1d ago
Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants
Healthcare Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants. The medicine is expected to be available for the upcoming 2024/25 RSV season. Separately, Astra Zeneca has received Japan approval for combination therapy to treat patients with advanced HR-positive breast cancer.
Seeking Alpha · 2d ago
AstraZeneca’s Ultomiris Approval Spurs Buy Rating Amid Growth in Rare Disease Segment
TipRanks · 2d ago
AstraZeneca Announced Earlier, Truqap Plus Faslodex Approved In Japan For Patients With Advanced HR-positive Breast Cancer
AstraZeneca's Truqap in combination with Faslodex has been approved in Japan for the treatment of breast cancer. The combination reduced the risk of disease progression or death by 50% in patients with breast cancer, the company says. The drug is already approved in the U.S.
Benzinga · 2d ago
AstraZeneca sues Arkansas to block drug-discount program
AstraZeneca sues Arkansas to block drug-discount program to include for-profit pharmacy chains such as CVS and Walgreens. AstraZeneca says the state measure violates the U.S. Constitution and patent law. Arkansas said it will challenge the lawsuit.
Reuters · 2d ago
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
AstraZeneca PLC announced it will buy Canadian drug developer Fusion Pharmaceuticals for $2.4 billion. The company is a specialist in cancer treatments. Fusion is developing next-generation radioconjugates, which deliver a radioactive isotope directly to cancer cells. AstraZeneca will take over Fusion's manufacturing and supply chain.
Barchart · 2d ago
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
NASDAQ · 2d ago
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 3d ago
UPDATE 1-China to speed up 'new productive forces', vice president says
China to bolster stability and security for global economy, vice president says at investment summit. Foreign businesses have been trying to reassure anxious foreign firms. China to speed up development of " productive forces" to attract foreign investment. The term "productive forces" was coined by President Xi Jinping last September.
Reuters · 3d ago
QQQ ETF Update, 3/26/2024 
Invesco QQQ ETF is down 0.72% in the past 5 days but has risen 45.54% over the past year. The Invesco  QQQETF is a Moderate Buy. The Street’s average price target of $494.06 implies an upside of about 11.09%. The five holdings with the highest upside potential are Warner Bros.
TipRanks · 3d ago
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
NASDAQ · 3d ago
Wall Street Lunch: Calhoun To Leave Boeing
Wall Street Lunch: Boeing's top boss Dave Calhoun plans to step down at the end of the year. Mizuho turns cautious on the EV sector, downgrades Tesla, Rivian, and Nio. Look beyond the Magnificent 7 to the GRANOLAS in Europe - Goldman Sachs.
Seeking Alpha · 3d ago
2 More Potential Biotech Buyout Targets
Oncology is projected to reach $375 billion in sales by 2027. The oncology space continues to be a hot and active area for M&A activity. Exelixis is one of two smaller companies that appear to be logical buyout targets for larger companies. The company is a mid-cap oncologist with a strong pipeline.
Seeking Alpha · 3d ago
German industry sceptical of China's vow to treat foreign firms equally
German industry sceptical of China's vow to treat foreign firms equally China pledges equal treatment for foreign firms German VDMA: announcement part of 'friendly signs' offensive Move aimed at keeping foreign firms engaged in China. German direct investment in China rose to a record high of 11.9 billion euros last year.
Reuters · 3d ago
AstraZeneca’s Ultomiris Revolutionizes NMOSD Treatment
TipRanks · 4d ago
Weekly Report: what happened at AZN last week (0318-0322)?
Weekly Report · 4d ago
AstraZeneca Announces FDA Approval For Ultomiris - Quick Facts
NASDAQ · 4d ago
Sanofi: My Top Pick In Big Pharma
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time AZN stock news. You can receive the latest news about Astrazeneca Plc through multiple platforms. This information may help you make smarter investment decisions.
About AZN
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.